Andrew J. Cutler, MD

Idiopathic hypersomnia, characterized by excessive daytime sleepiness (EDS), has an estimated population prevalence up to 1.5%. Psychiatric medications may exacerbate EDS and, conversely, idiopathic hypersomnia treatments may exacerbate psychiatric...

In pooled analyses, xanomeline/trospium was generally well tolerated. The most common adverse events were mild or moderate, transient, and consistent with the activity of xanomeline and trospium at muscarinic...

A durable improvement in MDD symptoms for up to 1 year was observed with esmethadone with high rates of response and remission.

Although this trial of esmethadone did not meet its primary outcome, some secondary and post hoc outcomes were promising.

Most patients with MDD achieved response after 14 days of zuranolone treatment. For patients who responded to their first treatment, the time to repeat treatment was over 4 months.

Treating attention-deficit/hyperactivity disorder (ADHD) in adults can improve long-term outcomes, such as reducing suicidal behavior and mortality. This study evaluated the efficacy and safety of amphetamine extended-release tablets in...